



Dr. Reddy's Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills
Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900
Fax: + 91 40 4900 2999
Email: mail@drreddys.com
Web: www.drreddys.com

January 10, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Following our intimation dated September 13, 2025 regarding the Pre-Approval Inspection (PAI) by United States Food & Drug Administration (USFDA) at our biologics manufacturing facility in Bachupally, Hyderabad, we wish to inform you that we have received a Post- Application Action Letter (PAAL) from the USFDA in relation to the response submitted.

The company will work closely with the USFDA and is committed to addressing the queries specified in the PAAL.

This is for your information and records.

Thanking you,

Yours faithfully,
For **Dr. Reddy's Laboratories Limited**

K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR